UNSPSC 51131904: Human blood plasma

This classification denotes a protein-based fluid (sometimes also called simulated body fluid) or that residual portion of blood that is left after removal of blood cells by centrifugation without prior blood coagulation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 839MOZ74GK. European Medicines Agency schedules Human Blood Plasma in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB51727.

UNSPSC 51131904 Human blood plasma is a Commodity code describing the procurement of processed blood plasma for transfusion, therapeutic, or research use by state and local health systems, laboratories, and medical facilities. State and local governments purchase plasma primarily through hospital blood banks, public health departments, and regional medical centers to support emergency transfusions, chronic disease treatment, and diagnostic testing. Issuing bodies include state health departments, county hospitals, municipal medical centers, and independent hospital districts, often procuring plasma through standing agreements with blood collection organizations or via competitive RFQ and IFB processes when volumes or specifications change.

The source provided contains no recent state or local contract opportunities under this code. Without posted solicitations, geographic concentration and representative recent procurement activity cannot be characterized from current market data.